In ₹ Crore except Per Share Latest Annual | ALPA FY26 | BALPHARMA FY26 | KREBSBIO FY26 | NATCAPSUQ FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 9.27× | 26.71× | — | — | 26.71× -65% | |
| P/B | ◆ 0.70× | 2.04× | — | — | 2.04× -66% | |
| EV/EBITDA | -0.70× | 10.13× | ◆ -65.36× | — | -27.62× +97% | |
| Market Cap | ₹131 Cr | ₹168 Cr | ₹132 Cr | — | ₹150 Cr -13% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 4.61% | 0.81% | -23.07% | — | -11.13% +141% | |
| Revenue CAGR 5Y | 1.64% | ◆ 4.46% | -15.07% | — | -5.30% +131% | |
| Net Income CAGR 3Y | 3.80% | ◆ 34.14% | — | — | 34.14% -89% | |
| Revenue YoY (latest Q) | 25.22% | ◆ 34.53% | 27.42% | 7.76% | 27.42% -8% | |
| Net Income YoY (latest Q) | -91.67% | ◆ 445.66% | 53.33% | -2.93% | 53.33% -272% | |
| Profitability | ||||||
| EBITDA Margin | 3.11% | ◆ 10.24% | -22.97% | -0.83% | -0.83% +475% | |
| Net Income Margin | ◆ 13.35% | 2.03% | -71.35% | -13.17% | -13.17% +201% | |
| Return on Common Equity | 7.58% | 7.64% | ◆ 10.40% | -7.27% | 7.64% -1% | |
| Return on Capital Employed | 0.63% | ◆ 16.49% | -23.66% | -6.42% | -6.42% +110% | |
| Return on Assets | ◆ 5.83% | 1.68% | -10.37% | -5.81% | -5.81% +200% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.01× | 1.94× | ◆ -1.38× | 0.49× | 0.49× -98% | |
| Interest Coverage | ◆ 4.65× | 1.24× | -1.68× | -1.71× | -1.68× +377% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹106 Cr | ₹312 Cr | ₹23.7 Cr | ₹187 Cr | ₹187 Cr -43% | |
| Net Income | ₹14.1 Cr | ₹6.3 Cr | −₹16.9 Cr | −₹24.7 Cr | −₹16.9 Cr +183% | |
| Total Assets | ₹242 Cr | ₹376 Cr | ₹163 Cr | ₹424 Cr | ₹376 Cr -36% | |
| EPS | ₹6.71 | ₹3.95 | ₹-7.85 | ₹-23.84 | ₹-7.85 +185% | |
| Book Value per Share | ₹88.53 | ₹51.66 | ₹-75.49 | ₹225.99 | ₹51.66 +71% | |